Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Return on Equity (ROE) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The investment activity ratios demonstrate a general trajectory of stabilization followed by a marked increase in operational efficiency regarding asset and equity utilization toward the conclusion of the observed period.
- Net Fixed Asset Turnover
- A mild downward trend is observed from March 2022, where the ratio stood at 5.18, reaching a low of 4.88 by March 2023. This was followed by a recovery phase that peaked at 5.28 in December 2023. Throughout 2024 and 2025, the ratio remained relatively stable, fluctuating within a narrow range between 5.11 and 5.28, suggesting a consistent ability to generate revenue from fixed asset investments.
- Total Asset Turnover
- The total asset turnover remained stagnant at 0.43 for the duration of 2022. A gradual improvement began in 2023 and accelerated in early 2024, reaching 0.52 by June 2024. Following a period of consolidation between 0.48 and 0.52 through 2025, a significant increase to 0.60 was recorded in June 2026, indicating an enhanced efficiency in utilizing the overall asset base to drive sales.
- Equity Turnover
- Equity utilization exhibited the highest level of volatility among the analyzed ratios. A steady decline from 1.37 in March 2022 to 1.18 in December 2023 was abruptly reversed in March 2024, with the ratio jumping to 1.56. After fluctuating and eventually dipping to 1.24 in March 2026, a sharp escalation to 2.52 occurred in June 2026. This final surge indicates a substantial increase in the volume of revenue generated relative to shareholder equity.
Net Fixed Asset Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Product sales | ||||||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Net fixed asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Net fixed asset turnover
= (Product salesQ2 2026
+ Product salesQ1 2026
+ Product salesQ4 2025
+ Product salesQ3 2025)
÷ Property, plant and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of long-term investment activity reveals a period of relative stability in asset utilization efficiency, characterized by a slight contraction followed by a recovery and subsequent stabilization. The net fixed asset turnover ratio fluctuated within a narrow band, indicating a consistent relationship between the company's fixed asset base and its ability to generate product sales.
- Net Fixed Asset Turnover Trends
- A gradual decline in the turnover ratio is observed from March 2022, where the ratio stood at 5.18, reaching a trough of 4.88 between March and September 2023. This period indicates a temporary decrease in the efficiency of fixed assets in generating revenue. However, a recovery phase followed, with the ratio peaking at 5.28 by December 2024. Toward the end of the observed period, the ratio stabilized, ending at 5.11 in June 2026, suggesting a return to long-term historical norms.
- Revenue Generation and Asset Correlation
- Product sales exhibited a general upward trajectory, increasing from 6,534 million USD in March 2022 to 7,627 million USD by June 2026, with a peak of 7,903 million USD in December 2025. The fluctuations in the turnover ratio closely mirror these revenue shifts. Specifically, the improvement in the ratio during 2024 was driven by strong sales growth that outpaced the expansion of the fixed asset base, thereby enhancing operational leverage.
- Fixed Asset Investment Patterns
- The net property, plant, and equipment balance demonstrated a slow and steady increase, rising from 5,253 million USD in March 2022 to 5,833 million USD by June 2026. This controlled growth in the asset base prevented significant volatility in the turnover ratio. The stability of the net fixed asset turnover suggests that capital expenditures were aligned with revenue growth requirements, avoiding over-investment that would have otherwise diluted asset productivity.
Total Asset Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Product sales | ||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Total asset turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Total asset turnover
= (Product salesQ2 2026
+ Product salesQ1 2026
+ Product salesQ4 2025
+ Product salesQ3 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio exhibits a distinct transition from a period of stagnation to one of increasing efficiency over the analyzed timeframe. From March 2022 through December 2023, the ratio remained virtually flat, fluctuating narrowly between 0.43 and 0.44. However, beginning in early 2024, a sustained upward trend emerged, culminating in a peak ratio of 0.60 by June 2026.
- Revenue Performance
- Product sales demonstrate consistent stability with a slight positive bias. Quarterly revenues generally fluctuated between 6.1 billion and 7.9 billion US dollars. While sales experienced periodic volatility, the overall trajectory supported the growth in turnover ratios by maintaining a strong revenue floor.
- Asset Base Dynamics
- A significant contraction in the total asset base is the primary driver of the improved turnover ratio. Total assets remained stable around 62 billion to 63 billion US dollars until March 2024, after which a downward trend commenced. By June 2026, total assets decreased to approximately 49.4 billion US dollars, representing a substantial reduction in the denominator of the turnover calculation.
- Asset Utilization Efficiency
- The increase in total asset turnover from 0.43 to 0.60 indicates a marked improvement in how effectively assets are utilized to generate sales. This improvement was not driven by an exponential increase in product sales, but rather by a leaner balance sheet. The most aggressive improvement occurred between December 2023 and June 2024, where the ratio climbed from 0.43 to 0.52, and again in the final quarter of the period, reaching 0.60.
Equity Turnover
| Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||
| Product sales | ||||||||||||||||||||||||
| Total Gilead stockholders’ equity | ||||||||||||||||||||||||
| Long-term Activity Ratio | ||||||||||||||||||||||||
| Equity turnover1 | ||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||
| Equity Turnover, Competitors2 | ||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q2 2026 Calculation
Equity turnover
= (Product salesQ2 2026
+ Product salesQ1 2026
+ Product salesQ4 2025
+ Product salesQ3 2025)
÷ Total Gilead stockholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of equity turnover reveals a volatile trend driven primarily by significant fluctuations in total stockholders' equity rather than consistent shifts in product sales. While product sales exhibited a general upward trajectory with seasonal dips, the efficiency of equity utilization was heavily impacted by sharp reductions in the equity base.
- Equity Turnover Trend Analysis (2022–2023)
- Between March 31, 2022, and December 31, 2023, a gradual decline in the equity turnover ratio is observed, falling from 1.37 to 1.18. This downward trend occurred despite a general increase in product sales, indicating that the growth in total stockholders' equity—which rose from 19,927 million to 22,833 million—outpaced the growth in revenue during this period.
- Impact of Equity Reductions (2024–2025)
- A sharp reversal in the turnover trend occurred in the first quarter of 2024, where the ratio spiked to 1.56. This increase was not driven by a surge in sales, but by a substantial decrease in total stockholders' equity, which dropped to 17,539 million. Following this event, the ratio entered a period of gradual contraction, ending at 1.27 by December 31, 2025, as equity began to recover and trend upward toward 22,703 million.
- Anomalous Spike in 2026
- The most significant deviation in the data is noted in June 30, 2026, where the equity turnover ratio surged to 2.52. This peak is directly correlated with a precipitous decline in stockholders' equity, which fell to 11,829 million. Because the equity denominator decreased drastically while product sales remained robust at 7,627 million, the ratio reached its highest level in the analyzed timeframe, suggesting a significant change in the capital structure or a large-scale distribution of equity.
In summary, the equity turnover ratio for the period demonstrates that the company's asset utilization efficiency, as measured against equity, is highly sensitive to changes in the equity balance. The observed spikes in turnover are indicative of equity contraction rather than organic operational growth.